KCT0003812
Not yet recruiting
未知
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of MS on improving liver function
ChongKunDang Healthcare0 sites80 target enrollmentTBD
ConditionsDiseases of the digestive system
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Diseases of the digestive system
- Sponsor
- ChongKunDang Healthcare
- Enrollment
- 80
- Status
- Not yet recruiting
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adult male and female between 19\-75 years
- •2\) ?\-GTP \= 70 IU/L and \= 180 IU/L
- •3\) In the alcohol drinking style survey, Subject who drinks more than average 14 unit of male, 7 unit of female per week during the past month.
- •4\) Subject who voluntarily agrees to participate and sign in informed consent form
Exclusion Criteria
- •1\) Subject who are admitted to hospital, medication or rehabilitation due to alcohol use disorder ? related disorder, heart disease, central nervous disorder, etc
- •2\) Abdominal ultrasound exam showed liver cirrhosis or liver cancer patients
- •3\) Subject who more than 3times the upper limit of normal AST(GOT) or ALT(GPT) of clinical trial institution
- •4\) Subject who more than 3times the upper limit of normal ALP or Platelet \= 105/µL or AFP \> 10ng/mL
- •5\) Subject who have been diagnosed with viral hepatitis
- •6\) Subjcet who were positive HBs Ag or HCV Ab in screening test
- •7\) Subject who Albumin \= 3g/dl or Total Bilirubin \= 3mg/dl
- •8\) Subject who more than 1\.5times the upper limit of normal Creatinine
- •9\) Uncontrolled thyroid disease patient
- •10\) Subject who was taking drugs the affects liver function within 4 weeks of study(antituberculosis drugs, anticonvulsants, arthrifuges, antidepressants and other drugs that may cause hepatotoxicity)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HT083 on mild OsteoarthritisKCT0004925The Catholic University of Korea, Uijeongbu St. Mary’s Hospital100
Recruiting
Not Applicable
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of KBL693 on atopic dermatitis in childreDiseases of the skin and subcutaneous tissueKCT0005895Kobiolabs159
Recruiting
Not Applicable
Clinical trial for the evaluation of the efficacy and safety of NIHHS-18-42458 on improving liver functioDiseases of the digestive systemKCT0004392ational Institute of Horticultural and Herbal Science90
Completed
Not Applicable
Clinical trial for the evaluation of the efficacy and safety of KACC91563 on atopic dermatitis in childreKCT0003822Aram100
Recruiting
Not Applicable
A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of TabetriTM on atopic dermatitis in childreDiseases of the skin and subcutaneous tissueKCT0002640utri Biotech60